Lima J J, Conti D R, Goldfarb A L, Golden L H, Jusko W J
Eur J Clin Pharmacol. 1978 Jun 19;13(4):303-8. doi: 10.1007/BF00716367.
A pharmacokinetic approach was employed to design a dosing regimen for the i.v. use of procainamide (PA) which consisted of a loading infusion given over one hour followed by a maintenance infusion. Therapeutic serum concentrations of PA were achieved in less than 15 min, and toxic serum concentrations were avoided in 12 patients. A mean maximum serum concentration of PA of 5.78 mg/l was obtained with a loading infusion of 16.6 mg/min PA HCl. An average steady-state serum concentration of PA of 5.05 mg/l was obtained with a mean maintenance infusion of 222 mg/hour PA HCl. The total body clearance of PA in slow and fast acetylators averaged 31 and 43 l/h respectively. Use of PA in cardiac patients by i. v. infusion can be safe and effective therapy.
采用药代动力学方法设计了静脉注射普鲁卡因胺(PA)的给药方案,该方案包括1小时的负荷输注,随后是维持输注。在不到15分钟内达到了PA的治疗血清浓度,并且12例患者避免了出现毒性血清浓度。盐酸PA负荷输注速度为16.6mg/min时,PA的平均最大血清浓度为5.78mg/l。盐酸PA平均维持输注速度为222mg/小时时,PA的平均稳态血清浓度为5.05mg/l。慢乙酰化者和快乙酰化者体内PA的总体清除率分别平均为31l/h和43l/h。通过静脉输注使用PA对心脏病患者而言可能是一种安全有效的治疗方法。